Core Viewpoint - Kyndryl Holdings is under investigation for potential claims related to significant losses suffered by investors following the company's disclosure of issues with its cash management practices and internal controls, leading to a substantial decline in stock price [1]. Company Summary - Kyndryl Holdings, Inc. disclosed on February 9, 2026, that its Audit Committee is reviewing cash management practices and related disclosures, particularly concerning the adjusted free cash flow metric [1]. - The company expects to report material weaknesses in internal control over financial reporting for multiple reporting periods [1]. - Kyndryl stated that its previous assessment of internal control and the independent auditor's opinion in its Annual Report for the fiscal year ended March 31, 2025, should no longer be relied upon [1]. - The company announced the immediate departures of its Chief Financial Officer and General Counsel [1]. - Kyndryl filed a Form NT 10-Q indicating a delay in the filing of its Quarterly Report on Form 10-Q [1]. - Following these disclosures, Kyndryl's stock price declined approximately 50% on February 9, 2026 [1].

Core Viewpoint - Aquestive Therapeutics, Inc. experienced a significant stock decline of approximately 40% after the FDA identified deficiencies in its New Drug Application for Anaphylm, raising concerns about the drug's approvability ahead of the January 31, 2026 PDUFA action date [4]. Company Overview - Aquestive Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with severe allergic reactions, including anaphylaxis [4]. Legal Investigation - Faruqi & Faruqi, LLP, a national securities law firm, is investigating potential claims against Aquestive Therapeutics for investors who suffered significant losses due to the recent stock decline [2][3].

Core Viewpoint - A class action lawsuit has been filed against Fermi, Inc. for allegedly making materially false and misleading statements regarding its business operations and prospects, particularly concerning the Project Matador campus [4][8]. Allegation Details - The lawsuit claims that Fermi overstated tenant demand for the Project Matador campus [4] - It is alleged that the company did not adequately disclose its reliance on a single tenant's funding commitment for the project's construction [4] - There is a significant risk that the tenant may terminate its funding commitment, which was not disclosed [4] - As a result, the positive statements made by the defendants about the company's business were misleading and lacked a reasonable basis [4] Next Steps - Investors who purchased Fermi shares and suffered losses can contact the law firm for more information and to discuss their rights [5][8] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is March 6, 2026 [8]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. (Beta Bionics) due to significant stock losses and possible misleading statements made by the company [2][3]. Company Investigation - The investigation centers on whether Beta Bionics issued misleading statements or failed to disclose important information to investors [3]. - Following the announcement of fewer patient starts than analysts estimated for the fourth quarter, Beta Bionics' shares dropped approximately 37% on January 9, 2026 [3]. Legal Options for Investors - Investors who suffered significant losses in Beta Bionics stock or options are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][4].

Core Viewpoint - A class action lawsuit has been filed against Ramaco Resources, Inc. for allegedly making materially false and misleading statements regarding its mining operations, particularly at the Brook Mine, leading to significant investor losses during the specified class period [2][7]. Allegation Details - The lawsuit claims that Ramaco failed to disclose that no significant mining activity had commenced at the Brook Mine after its groundbreaking, and that the company overstated its development progress [7]. - A report by Wolfpack Research described the Brook Mine as a "hoax" and indicated that no active work had taken place, contradicting the company's positive statements about its operations [7]. Stock Performance - Following the publication of the Wolfpack Research report on October 23, 2025, Ramaco's stock price dropped by $3.81, or 9.6%, closing at $36.01 per share, with unusually high trading volume [7].

Core Insights - Rezolute, Inc. is under investigation by Faruqi & Faruqi, LLP due to significant stock losses following disappointing results from its Phase 3 clinical trial for its lead drug candidate, ersodetug [2][3]. Group 1: Company Performance - Rezolute's shares experienced a dramatic decline on December 11, 2025, dropping from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% decrease [3][4]. - The Phase 3 sunRIZE clinical trial for ersodetug did not meet its primary and key secondary endpoints, with the highest dose showing non-significant reductions in hypoglycemia events compared to placebo [3]. Group 2: Legal and Investor Actions - Faruqi & Faruqi, LLP is encouraging investors who suffered significant losses in Rezolute stock or options to contact them to discuss potential legal options [1]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [2].

Core Viewpoint - A class action lawsuit has been filed against Klarna Group plc on behalf of investors who acquired Klarna securities during the specified class period, alleging that the company failed to disclose material financial risks related to its IPO [1][3]. Group 1: Lawsuit Details - The lawsuit targets investors who purchased Klarna securities from September 7, 2025, to December 22, 2025, including shares from the September 2025 IPO [1][2]. - Investors have until February 20, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Group 2: Financial Risks and IPO Performance - The lawsuit claims that Klarna's IPO documents did not adequately disclose significant financial risks, particularly the potential for a sharp increase in loss reserves due to the high-risk profiles of its customers [3]. - Following a report on November 18, 2025, indicating that Klarna had set aside more provisions for credit losses than the market expected, the company's share price fell by 21% from the IPO price of $40 to $31.31 [4].

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc due to misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints [1][2]. Group 1: Lawsuit Details - The lawsuit, Megan Dodge v. Mereo BioPharma Group plc, was initiated in the United States District Court for the Southern District of New York for investors who purchased American Depositary Shares (ADS) between June 5, 2023, and December 26, 2025 [1]. - Investors are encouraged to participate in the lawsuit before the April 6, 2026 deadline to potentially recover losses [5]. Group 2: Study Results - Mereo announced on December 29, 2025, that neither the ORBIT nor the COSMIC Phase 3 studies achieved statistical significance, failing to meet the primary endpoint of reducing annualized clinical fracture rates compared to placebo or bisphosphonates [3]. - Despite improvements in bone mineral density, the studies did not yield the expected results, leading to significant investor concerns [2][3]. Group 3: Market Reaction - Following the announcement of the study results, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, marking a decline of over 87.7% [4].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. for allegedly misleading investors regarding its accounts receivable practices during the Class Period from July 18, 2024, to November 12, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Ardent misrepresented its process for determining the collectability of accounts receivable, stating it relied on detailed historical reviews, while in reality, it used a 180-day cliff method for reserving accounts [3]. - On November 12, 2025, Ardent announced a $43 million reduction in revenue due to changes in accounting estimates for accounts receivable collectability and a $54 million increase in professional liability reserves, leading to a significant drop in share price by approximately 33.8% [4]. Group 2: Legal Process - The lead plaintiff deadline for the class action is set for March 9, 2026, and applications filed after this date will not be considered [2]. - The lead plaintiff plays a crucial role in overseeing the litigation and can influence key decisions, including litigation strategy and settlement [2].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Corcept Therapeutics Incorporated for possible violations of federal securities laws and unlawful business practices following a significant stock price drop after an FDA response regarding a new drug application [1][2]. Investigation Details - On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter regarding its New Drug Application for relacorilant, which is intended for treating hypertension secondary to hypercortisolism. The FDA acknowledged that Corcept's pivotal GRACE trial met its primary endpoint but required additional evidence of effectiveness, leading to a stock price decline of $35.40 per share, or 50.42%, closing at $34.80 [2]. Next Steps - Investors who purchased or acquired Corcept shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims. There is no cost or obligation for this consultation [3]. About Bragar Eagel & Squire, P.C. - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in various types of litigation, including securities and commercial cases. The firm operates nationwide and handles cases in both federal and state courts [4].